CHMP recommends against Mirati’s KRAS rival, in favor of Pfizer’s RSV vaccine, other drugs

The Eu­ro­pean Med­i­cines Agency’s hu­man med­i­cines com­mit­tee (CHMP) rec­om­mend­ed against con­di­tion­al au­tho­riza­tion for Mi­rati’s KRAS G12C in­hibitor Kraza­ti in non-small cell lung can­cer this week, while giv­ing the thumbs-up to 14 oth­er drugs, in­clud­ing Pfiz­er’s RSV vac­cine.

CHMP said on Fri­day that there were un­cer­tain­ties about how well Kraza­ti (ada­gra­sib) worked, adding that “com­pre­hen­sive da­ta for this med­i­cine were not yet avail­able” and cri­te­ria for a con­di­tion­al mar­ket­ing au­tho­riza­tion were un­met.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN